Olema Oncology, Inc 10-Q for FY2026 Q3
Olema Oncology, Inc. (OLMA)
10-Q
2026-11-10
For: 2026-09-30
View Original
Added on
November 10, 2026
About this 10-Q
Olema Oncology, Inc filed this 10-Q on November 10, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).
Olema reported a $189.9 million net loss for the nine months ended September 30, 2026. Palazestrant’s Phase 3 OPERA-01 top-line results are expected in the first quarter of 2027, followed by an NDA submission in 2027. AI summary
Headline figures
Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Net loss
- $73.6M
- compared with a net loss of $42.22M a year earlier
- Diluted EPS
- -$0.73
- compared with -$0.49 a year earlier